Compare REFR & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | MYO |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Industrial Specialties |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 33.3M |
| IPO Year | 1995 | 2017 |
| Metric | REFR | MYO |
|---|---|---|
| Price | $0.74 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 34.2K | ★ 335.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,488,642.00 | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.73 | $0.61 |
| 52 Week High | $2.70 | $3.22 |
| Indicator | REFR | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 66.87 |
| Support Level | N/A | $0.90 |
| Resistance Level | $1.02 | $1.10 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.85 | 81.85 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.